KIT and ovarian cancer: Taken together, these data indicate that DDB2 silencing is able to facilitate the ovarian cancer cell dedifferentiation, characterized by both CD44−CD117− to CD44+CD117+ cell conversions and ALDH− to ALDH+ cell conversions, as well as the non-tumorigenic to tumorigenic cell conversions.